What is Xeris Biopharma Holdings, Inc.'s debt-to-equity?

Xeris Biopharma Holdings, Inc. (XERS) reported debt-to-equity of 19.9× in Q1 2026.

What is the long-term trend for Xeris Biopharma Holdings, Inc.'s debt-to-equity?

Over 3 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s debt-to-equity has grown at a 94.1% compound annual growth rate (CAGR), from 2.6× to 18.9×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Xeris Biopharma Holdings, Inc. XERS Debt-to-equity

Debt-to-equity at other companies

Eli LillyLLY

1.4×-1.1×

Corcept TherapeuticsCORT

0×0.0×

Eton Pharmaceuticals, Inc.ETON

1×-0.2×

Ultragenyx PharmaceuticalRARE

3.7×—

Zevra Therapeutics, Inc.ZVRA

0×-1.5×

ANI PharmaceuticalsANIP

0.5×-0.2×

Other financials

Income statement

See full

Revenue$83.1M+38.3%

Gross profit$72.6M+41.2%

Operating income$7.9M+356%

Net income$2.2M+124%

EPS (diluted)$0.01+117%

Balance sheet

See full

Cash & equivalents$111.8M+91.2%

Total debt$258.6M-3.8%

Total equity$13.0M+137%

Total assets$392.0M+24.3%

Cash flow

See full

Operating cash flow$9.9M+198%

CapEx$131.0K—

Free cash flow-$29.1M—

Valuation

See full

Market cap$1.28B+18.3%

Enterprise value$1.42B+8.7%

P/E106.4×—

P/S4.1×-0.8×

Profitability

See full

Gross margin85.9%+3.7pp

Operating margin11.4%+7.7pp

Net margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-209.8%—

Current ratio2.1×+0.4×

Where this comes from

Calculated from Xeris Biopharma Holdings, Inc.’s reported figures.

total debt/total stockholders equity=19.9×

Based on the most recent quarter.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s debt-to-equity?: Xeris Biopharma Holdings, Inc. (XERS) reported debt-to-equity of 19.9× in Q1 2026.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s debt-to-equity?: Over 3 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s debt-to-equity has grown at a 94.1% compound annual growth rate (CAGR), from 2.6× to 18.9×.
What does debt-to-equity mean?: Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.